[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100187017":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":35,"centralContacts":11,"locations":39,"responsibleParty":87,"collaborators":11,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":11,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":11,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":115,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL",null,[13,14],"Drug: (CP-6890,550) Tofacitinib","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 2",[18,14],"Drug: (CP-690,550) Tofacitinib",[20,25,29,33],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","(CP-6890,550) Tofacitinib","2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks",[9],{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"(CP-690,550) Tofacitinib","2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks",[16],{"type":21,"name":26,"description":27,"armGroupLabels":34,"otherNames":11},[16],[36],{"name":37,"affiliation":5,"role":38},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[40,53,63,73,82],{"facility":41,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":11},"Dermatology Research Associates","Los Angeles","California","90045","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-118.24368,34.05223,{"lat":51,"lon":50},{"facility":54,"status":11,"city":55,"state":56,"zip":57,"country":45,"countryCode":46,"cosmosGeoPoint":58,"geoPoint":62,"contacts":11},"Olympian Clinical Research","Tampa","Florida","33609",{"type":48,"coordinates":59},[60,61],-82.45843,27.94752,{"lat":61,"lon":60},{"facility":64,"status":11,"city":65,"state":66,"zip":67,"country":45,"countryCode":46,"cosmosGeoPoint":68,"geoPoint":72,"contacts":11},"Menter Dermatology Research Institute","Dallas","Texas","75246",{"type":48,"coordinates":69},[70,71],-96.80667,32.78306,{"lat":71,"lon":70},{"facility":74,"status":11,"city":75,"state":66,"zip":76,"country":45,"countryCode":46,"cosmosGeoPoint":77,"geoPoint":81,"contacts":11},"Center for Clinical Studies","Houston","77004",{"type":48,"coordinates":78},[79,80],-95.36327,29.76328,{"lat":80,"lon":79},{"facility":74,"status":11,"city":75,"state":66,"zip":83,"country":45,"countryCode":46,"cosmosGeoPoint":84,"geoPoint":86,"contacts":11},"77030",{"type":48,"coordinates":85},[79,80],{"lat":80,"lon":79},{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100187017","phase-2-study-of-the-mechanism-of-action-of-cp-690550-in-the-skin-of-subjects-with-moderate-to-severe-chronic-plaque-psoriasis-100187017",true,"NCT01710046","Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis","An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Adults over 18 years of age with a diagnosis of chronic moderate to severe plaque psoriasis for at least 12 months; in generally good health; on stable dose of non-prohibited medications; able to stop current psoriasis therapy (systemic or topical) for several weeks prior to and during study participation.\n\nExclusion Criteria:\n\n* Serious underlying disease including viral disorders such as hepatitis or HIV or skin condition that would interfere with skin biopsies or evaluation of psoriasis; conditions that could interfere with drug absorption after oral administration; history of malignancy or auto-immune disease.\n* Use of oral or injected corticosteroids (steroids).",false,"ALL","18 Years",{"count":100,"type":101},12,"ACTUAL","INTERVENTIONAL",[104],"PHASE2","There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.",[107],"Plaque Psoriasis",[109,110,111,112,113,114],"plaque psoriasis","tofacitinib","biopsy","Janus Kinase","randomized placebo controlled clinical trial","psoriasis vulgaris","COMPLETED","2015-03-30",{"date":118,"type":119},"2015-04-13","ESTIMATED",{"date":121,"type":11},"2013-03",{"date":123,"type":101},"2013-11",{"name":5,"class":6},5]